Better Buy: Aurora Cannabis (TSX:ACB) vs Aphria Inc. (TSX:APHA)

As Aurora Cannabis (TSX:ACB)(NYSE:ACB) flexes its muscles and builds up inventory, Aphria Inc. (TSX:APHA)(NYSE:APHA) is becoming powerless to compete with the production champion.

| More on:
Financial technology concept.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The battle to win investors over in the cannabis space hasn’t weakened. Actually, it has become a war of attrition. Production king Aurora Cannabis (TSX:ACB)(NYSE:ACB) should be a shoe-in for market leadership. But can Aphria Inc. (TSX:APHA)(NYSE:APHA) slay the giant?

Cannabis producers are still in the limelight despite disappointing bottom line results. The top-tier, middle rung, and lower-tier industry players are on the level field right. All of them need to convert their exponential revenue growth into “real” profits. Investors are waiting grudgingly.

The pitch for Aurora Cannabis

The euphoria after enactment of the Cannabis Act last October quickly subsided because of supply shortages and the delayed opening of retail cannabis stores. But these problems somehow favour Aurora Cannabis. Being the largest cannabis producer, the company is expected to deliver during crunch time.

Aurora Cannabis reported sales of nine metric tons of marijuana during the fiscal third quarter. Production nearly doubled toward the end of the quarter as total harvest reached 15,590 kilograms. Overall, the Aurora Sky and Bradford facilities would yield an annual production output of 150,000 kilograms.

Based on their earnings report, net revenue rose 20% quarter-over-quarter amounting to $65 million. Recreation sales also grew by 37% versus the previous quarter.  Still, Aurora incurred $158-million loss in the quarter ended March 31, 2019. The company managed to cut the prior quarter’s losses by 33.6%

Analysts see Aurora Cannabis treading the right path to profitability. If Aurora Sky will continue to scale development at Aurora Sky, then gross margins could jump to 60% if not more. By this quarter’s end, total production would reach 25,000 kilograms.

In terms of stock performance, APHA is up over 72.12% year-to-date. With an estimated sales growth of +541.40% this year, analysts are forecasting a price appreciation of +41.4% or $16.50 at best. Aurora Cannabis is taking it one step at a time. Also, there is no impetus to rush into cannabis drinks. They know the right time will come.

Doomsday for Aphria?

It would be a pity to see Aphria losing steam. After recovering from a hostile takeover bid and short-selling allegations, the company was able to regain its bearings. APHA is up over 20.14% year-to-date and earlier this month, analysts are projecting as much as +175% stock price gain. The company has the makings of a giant slayer. However, another controversy is emerging.

Negative publicity has always put Aphria’s plans on hold. President Jakob Ripshtein has resigned and is heading for the exit door next month. This is a major blow indeed. Aphria can’t afford another issue that could frighten investors. A downtrend might develop from here.

With the fate of Aphria hanging in the balance again, the risks are higher. The loss of the topmost executive with extensive experience in the beverages industry dimmed their chances of penetrating the upcoming cannabis-infused beverage market.

Aurora Cannabis is a clear winner between the two weed stocks. The company will stand tall in the near-future, while Aphria might be crawling on its belly hoping for a white knight to rescue them.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »